A Phase 2 interventional study of Azacitidine and Lenalidomide in Acute Myeloid Leukemia and Acute Myelogenous Leukemia, sponsored by Celgene. Completed at 30 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-06-25.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 71st largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2012, is one of 105 in phase 2, and was the 38th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 133 · Phase 3 31 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 211 interventional studies. Of the 100 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 214 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 9 (25%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2012, is one of 8 in phase 2, and was the 9th registered.
Bristol-Myers Squibb’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
25 of the studies testing azacitidine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT06783790Institute of Hematology & Blood Diseases Hospital, ChinaAvapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | 2026-12 |
| NCT06066905Guangdong Provincial People's HospitalA Study of Chidamide With AZA in MRD Positive AML After Transplant | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, from their registry updates:
Among Bristol-Myers Squibb’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
The study aim is to compare safety and efficacy of high-dose lenalidomide regimen, sequential azacitidine and lenalidomide and an azacitidine in persons ≥65 years with newly-diagnosed acute myeloid leukemia (AML).
On September 11, 2013, randomization into the continuous 50 mg lenalidomide only arm was temporarily suspended based on review of the data from the first 13 participants and a high rate of discontinuation (11/13 participants). The Data Monitoring Committee assessed the study data on September 20, 2013 and reported no safety concerns. The high rate of early discontinuation is inconsistent with the treatment duration required for testing the study primary endpoint of survival at one year. Consequently, Celgene has decided not to reopen the lenalidomide only arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Repeated cycles of azacitidine 75 mg/m\^2/day subcutaneous (SC) on Days 1-7 and lenalidomide 50 mg/day by mouth (PO) on Days 8-28 followed by a 14-day break plus best supportive care
Drug: Azacitidine · Drug: Lenalidomide · Other: Best Supportive Care (BSC)
Lenalidomide 50 mg PO daily for 28 days for the first 2 cycles and lenalidomide 25 mg daily for 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg daily PO plus best supportive care
Drug: Lenalidomide · Other: Best Supportive Care (BSC)
Repeated cycles of azacitidine 75mg/m\^2/day subcutaneous on Days 1-7 followed by a 21-day break plus best supportive care
Drug: Azacitidine · Other: Best Supportive Care (BSC)
Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
Also known as: Vidaza
Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
Also known as: Revlimid®, CC-5013
The use of BSC was considered as concomitant treatment and must be documented as concomitant medication. BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support
Kaplan Meier Estimates for One Year Survival
One-year survival rate was defined as all deaths within one year from the date of randomization. All others censored at the at year 1 or date of discontinuation
Time frame: Up to 24 months
Overall Survival
Overall Survival reported at the end of the study are for those participants who were alive at the end of the study
Time frame: From date of randomization until the date of the first documented date of progression or date of death of any cause; the overall median follow-up for survivng participants was 4.1 months (range 0.2 to 54.8 months)
Percentage of Participants With a Complete Response or Morphologic Incomplete Response.
Based on IWG response criteria for AML. Complete remission (CR), morphologic complete remission (CR) was defined as \< 5% bone marrow blasts, an absolute neutrophil count ≥ 1 x 10\^9/L, platelets ≥100 x 10\^9/L, and transfusion independence (no transfusions for 1 week prior to each assessment). No duration of these findings is required for confirmation of this response. Morphologic CR with incomplete blood count recovery (CRi) was defined as a morphologic complete remission but the ANC count may be \<1 x 10\^9/L and/or the platelet count may be \<100 x 10\^9/L. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
Time frame: Complete Response or Morphologic Incomplete Response data not analyzed.
Duration of Remission (DoR)
Duration of remission was defined as the time from the date of CR or CRi until relapse. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
Time frame: Duration of Remission (DoR) time frame not analyzed.
Cytogenetic Complete Remission Rate (CRc)
The CRc response category is comprised of the subset of participants who had abnormal cytogenetics at baseline and subsequently achieved CR during treatment in conjunction with a reversion to a normal karyotype. For the primary definition of CRc, a normal karyotype is defined as no clonal abnormalities after review of at least 10 metaphases using conventional cytogenetic techniques. Cytogenetic complete remission rate (CRc) 1) CR criteria met AND 2) Abnormal karyotype present at baseline AND 3) Reversion to normal karyotype at time of CR (based on ≥ 10 metaphases), where date of cytogenetic sample = date of BM sample used for the CR assessment. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
Time frame: Cytogenetic Complete Remission timeframe was not analyzed.
Percentage of Participants With an Overall Response Rate (CR +CRi+ PR)
Morphologic complete remission (CR) is defined as a leukemia-free state defined as less than 5% blasts in a one marrow aspirate with spicules and with at least 200 nucleated cells (there should be no blasts with auer rods) and ANC of ≥ 1 x 10\^9/L, a platelet count ≥ 100 x 10\^9/L, no transfusions for 1 week prior to each assessment. No duration of these findings is required for confirmation of this response. Morphologic complete remission with incomplete blood count recovery was defined as a morphologic complete remission but the ANC may be \< 1 x 10\^9/L and/or the platelet count may be \< 100 x 10\^9/L. Partial remission was defined as an ANC \> 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L with a \> 50% decrease in the percentage of bone marrow blasts to 5% to 25% (a blast count value of ≤ 5% may also be considered a partial remission if auer rods are present). Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
Time frame: Overall response rate time frame was not analyzed.
Progression-Free Survival (PFS)
PFS is defined as the time from randomization to the first observation of documented disease progression or death from any cause whichever occurred first. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
Time frame: Progression-Free survival data and time frame was not analyzed.
Event-Free Survival (EFS)
EFS was defined as the interval from the date of randomization to the date of treatment failure, progressive disease, relapse after CR or CRi, or death from any cause, whichever occurred first. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
Time frame: Event-Free survival time was not analyzed.
Relapse-Free Survival (RFS)
RFS is defined only for subjects that achieve CR and CRi and is measured as the interval from that date to the date of disease relapse, death from any cause, whichever occurs first, censoring at the last visit date for subjects alive in continuous CR/CRi. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
Time frame: Relapse-Free survival time frame was not analyzed.
Percentage of Participants With 30-Day Treatment-Related Mortality
30-day mortality rate was defined as death from any cause within 30 days after first dose.
Time frame: 30 days
Number of Participants With Treatment Emergent Adverse Events (TEAE)
TEAEs were defined as those events that started on or after the first day of study drug up until 28 days after the last dose of study drug; Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect; constitutes an important medical event. Severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); and according to the scale: Grade (Gr) 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
Time frame: From the first dose of study drug up to 28 days after the last dose of study drug; up to 15 May 2018
Number of Participants With a Second Primary Malignancy
Second primary malignancies were monitored as events of interest and reported as serious adverse events regardless of the treatment arm the participant was enrolled in.
Time frame: From randomization of the last participant up to a minimum of 4 years following discontinuation
Percentage of Participants Alive at One Year
Defined as the percentage of participants who survived at one year
Time frame: Up to 12 months
Participants were randomized at 25 sites in North America (Canada and the United States).
| Milestone | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Started | 15 | 39 | 34 |
| Safety population | 14 | 38 | 32 |
| Completed | 0 | 0 | 0 |
| Not completed | 15 | 39 | 34 |
| Withdrew: Adverse event | 4 | 7 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 6 | 3 |
| Withdrew: Death | 3 | 7 | 2 |
| Withdrew: Progressive disease | 5 | 13 | 16 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 |
| Withdrew: Other | 2 | 5 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
One-year survival rate was defined as all deaths within one year from the date of randomization. All others censored at the at year 1 or date of discontinuation
| months | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Kaplan Meier Estimates for One Year Survival | 3.00 (1.18 to 11.93) | 9.61 (3.18 to 19.31) | 13.67 (6.75 to NA) |
Based on IWG response criteria for AML. Complete remission (CR), morphologic complete remission (CR) was defined as \< 5% bone marrow blasts, an absolute neutrophil count ≥ 1 x 10\^9/L, platelets ≥100 x 10\^9/L, and transfusion independence (no transfusions for 1 week prior to each assessment). No duration of these findings is required for confirmation of this response. Morphologic CR with incomplete blood count recovery (CRi) was defined as a morphologic complete remission but the ANC count may be \<1 x 10\^9/L and/or the platelet count may be \<100 x 10\^9/L. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
No measurements were reported for this outcome.
Duration of remission was defined as the time from the date of CR or CRi until relapse. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
No measurements were reported for this outcome.
The CRc response category is comprised of the subset of participants who had abnormal cytogenetics at baseline and subsequently achieved CR during treatment in conjunction with a reversion to a normal karyotype. For the primary definition of CRc, a normal karyotype is defined as no clonal abnormalities after review of at least 10 metaphases using conventional cytogenetic techniques. Cytogenetic complete remission rate (CRc) 1) CR criteria met AND 2) Abnormal karyotype present at baseline AND 3) Reversion to normal karyotype at time of CR (based on ≥ 10 metaphases), where date of cytogenetic sample = date of BM sample used for the CR assessment. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
No measurements were reported for this outcome.
Morphologic complete remission (CR) is defined as a leukemia-free state defined as less than 5% blasts in a one marrow aspirate with spicules and with at least 200 nucleated cells (there should be no blasts with auer rods) and ANC of ≥ 1 x 10\^9/L, a platelet count ≥ 100 x 10\^9/L, no transfusions for 1 week prior to each assessment. No duration of these findings is required for confirmation of this response. Morphologic complete remission with incomplete blood count recovery was defined as a morphologic complete remission but the ANC may be \< 1 x 10\^9/L and/or the platelet count may be \< 100 x 10\^9/L. Partial remission was defined as an ANC \> 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L with a \> 50% decrease in the percentage of bone marrow blasts to 5% to 25% (a blast count value of ≤ 5% may also be considered a partial remission if auer rods are present). Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
No measurements were reported for this outcome.
PFS is defined as the time from randomization to the first observation of documented disease progression or death from any cause whichever occurred first. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
No measurements were reported for this outcome.
EFS was defined as the interval from the date of randomization to the date of treatment failure, progressive disease, relapse after CR or CRi, or death from any cause, whichever occurred first. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
No measurements were reported for this outcome.
RFS is defined only for subjects that achieve CR and CRi and is measured as the interval from that date to the date of disease relapse, death from any cause, whichever occurs first, censoring at the last visit date for subjects alive in continuous CR/CRi. Because of a high rate of discontinuation in one of the investigational cohorts, secondary endpoints were not analyzed.
No measurements were reported for this outcome.
30-day mortality rate was defined as death from any cause within 30 days after first dose.
| percentage of participants | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Percentage of Participants With 30-Day Treatment-Related Mortality | 13.3 | 17.9 | 5.9 |
TEAEs were defined as those events that started on or after the first day of study drug up until 28 days after the last dose of study drug; Serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect; constitutes an important medical event. Severity of AEs were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); and according to the scale: Grade (Gr) 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death
| participants | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Any TEAE | 14 | 38 | 32 |
| ≥1 TEAE related to study drug | 13 | 35 | 30 |
| ≥1 TEAE CTCAE Grade 3 or 4 TEAE | 14 | 34 | 29 |
| ≥1 TEAE CTCAE Gr 3 or 4 TEAE related to study drug | 11 | 25 | 18 |
| ≥1 TEAE CTCAE Grade 5 | 5 | 10 | 5 |
| ≥1 Serious TEAE | 13 | 29 | 25 |
| ≥1 Serious TEAE related to study drug | 10 | 16 | 7 |
| ≥1TEAE leading to discontinuation of study drug | 6 | 12 | 4 |
| ≥1TEAE leading to dose reduction of study drug | 0 | 8 | 2 |
| ≥1TEAE leading to dose interruption of study drug | 8 | 21 | 10 |
Defined as the percentage of participants who survived at one year
| Percentage of participants | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Percentage of Participants Alive at One Year | 21.4 (0.0 to 42.9) | 43.9 (27.9 to 59.9) | 52.3 (34.7 to 69.8) |
Overall Survival reported at the end of the study are for those participants who were alive at the end of the study
| months | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Overall Survival | 0.2 (0.2 to 0.2) | 7.1 (1.4 to 53.3) | 4.1 (0.2 to 54.8) |
Second primary malignancies were monitored as events of interest and reported as serious adverse events regardless of the treatment arm the participant was enrolled in.
| Participants | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Number of Participants With a Second Primary Malignancy | 0 | 0 | 3 |
Collected over From the date of randomization to 28 days after the last dose of study drug. Up to 15 May 2018.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | 7/14 (50%) | 13/14 (92.9%) | 14/14 (100%) |
| Azacitidine Plus Lenalidomide | 34/38 (89.5%) | 29/38 (76.3%) | 38/38 (100%) |
| Azacitidine | 29/32 (90.6%) | 25/32 (78.1%) | 32/32 (100%) |
| Event | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/14 | 16/38 | 8/32 |
| PneumoniaInfections and infestations | 3/14 | 4/38 | 7/32 |
| AnaemiaBlood and lymphatic system disorders | 2/14 | 2/38 | 2/32 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/14 | 2/38 | 1/32 |
| SepsisInfections and infestations | 2/14 | 1/38 | 2/32 |
| Septic shockInfections and infestations | 2/14 | 1/38 | 0/32 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 2/14 | 1/38 | 0/32 |
| Pulmonary infarctionRespiratory, thoracic and mediastinal disorders | 2/14 | 0/38 | 0/32 |
| FatigueGeneral disorders | 2/14 | 0/38 | 1/32 |
| CellulitisInfections and infestations | 0/14 | 3/38 | 1/32 |
| Event | Lenalidomide | Azacitidine Plus Lenalidomide | Azacitidine |
|---|---|---|---|
| NauseaGastrointestinal disorders | 4/14 | 19/38 | 22/32 |
| ConstipationGastrointestinal disorders | 7/14 | 24/38 | 17/32 |
| FatigueGeneral disorders | 8/14 | 15/38 | 14/32 |
| DiarrhoeaGastrointestinal disorders | 5/14 | 19/38 | 8/32 |
| HypokalaemiaMetabolism and nutrition disorders | 7/14 | 12/38 | 8/32 |
| Decreased appetiteMetabolism and nutrition disorders | 4/14 | 18/38 | 10/32 |
| Oedema peripheralGeneral disorders | 6/14 | 7/38 | 7/32 |
| AnaemiaBlood and lymphatic system disorders | 6/14 | 11/38 | 10/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/14 | 16/38 | 4/32 |
| Weight decreasedInvestigations | 5/14 | 15/38 | 10/32 |
Intent To Treat (ITT) includes all randomized participants
| Age, Continuous(years) | Lenalidomide | Azacitidine + Lenalidomide | Azacitidine | Total |
|---|---|---|---|---|
| Mean | 77.6 ± 5.47 | 75.5 ± 5.88 | 74.8 ± 4.96 | 75.97 ± 5.44 |
| Sex: Female, Male(Participants) | Lenalidomide | Azacitidine + Lenalidomide | Azacitidine | Total |
|---|---|---|---|---|
| Female | 3 | 17 | 15 | 35 |
| Male | 12 | 22 | 19 | 53 |
| Eastern Cooperative Oncology Group Performance Status(Participants) | Lenalidomide | Azacitidine + Lenalidomide | Azacitidine | Total |
|---|---|---|---|---|
| 0 = (Fully Active) | 4 | 4 | 10 | 18 |
| 1 = (Restrictive but ambulatory) | 9 | 28 | 17 | 54 |
| (Ambulatory but unable to work) | 2 | 7 | 6 | 15 |
| 3 = (Limited self care) | 0 | 0 | 0 | 0 |
| 4 = (Completely Disabled) | 0 | 0 | 0 | 0 |
| Missing | 0 | 0 | 1 | 1 |
| Peripheral Blast Blood Count(Participants) | Lenalidomide | Azacitidine + Lenalidomide | Azacitidine | Total |
|---|---|---|---|---|
| <1 X 10^9L | 11 | 31 | 27 | 69 |
| ≥1 X 10^9L | 4 | 8 | 7 | 19 |
Ran from Apr 2012 to primary completion in May 2015, 36 months.
Results were first posted in Jul 2016, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 36 months is close to that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azacitidine · Lenalidomide